Health Care & Life Sciences » Biotechnology | GTx Inc.

GTx Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
384.00
102.00
43.00
28.00
47.00
Gross Income
384.00
102.00
43.00
28.00
47.00
SG&A Expense
41,909.00
30,246.00
21,798.00
25,905.00
30,608.00
EBIT
42,293.00
30,348.00
21,841.00
25,933.00
30,655.00
Unusual Expense
1,306.00
8,804.00
3,081.00
8,163.00
-
Non Operating Income/Expense
1,488.00
259.00
57.00
46.00
216.00
Pretax Income
42,111.00
39,411.00
18,703.00
17,724.00
30,439.00
Consolidated Net Income
42,111.00
39,411.00
18,703.00
17,724.00
30,439.00
Net Income
42,111.00
39,411.00
18,703.00
17,724.00
30,439.00
Net Income After Extraordinaries
42,111.00
39,411.00
18,703.00
17,724.00
30,439.00
Net Income Available to Common
42,111.00
39,411.00
18,703.00
17,724.00
30,439.00
EPS (Basic)
6.70
4.80
1.50
1.22
1.75
Basic Shares Outstanding
6,305.70
8,180.80
14,036.50
14,559.50
17,441.30
EPS (Diluted)
6.68
4.82
1.47
1.22
1.75
Diluted Shares Outstanding
6,305.70
8,180.80
14,777.40
14,559.50
17,441.30
EBITDA
41,909.00
30,246.00
21,798.00
25,905.00
30,608.00

About GTx

View Profile
Address
175 Toyota Plaza
Memphis Tennessee 38103
United States
Employees -
Website http://www.gtxinc.com
Updated 09/14/2018
GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.